Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

By afschroeder • August 13, 2025

van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits J, Drakaki A, Mar N, Maroto Rey JP, Vulsteke C, Arafat W, Duran I, Dawson NA, Swami U, Gorla S, Moreno BH, Yu X, Lu YT, Bedke J. Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open. 2025 Aug 11;10(8):105544. doi: 10.1016/j.esmoop.2025.105544. Epub ahead of print. PMID: 40795788.

Tags: Bladder cancer, enfortumab vedotin, Hematology/Oncology, metastatic urothelial carcinoma, pembrolizumab, Phase III, Publications, subgroup analysis

Related Posts

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat[...]

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo[...]

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease

Prueksapraopong C, Fernandes A, Campo Fernandez B, Roy S, Hollis RP, Habtemariam B, Pellin D, Ceoldo G, Lin TY, Dang TT, Cornetta K, Romero Z,[...]